摘要
目的:观察维生素A、维生素E、重组人生长激素三联治疗矮小症患儿的效果。方法:选取138例矮小症患儿为研究对象,按照随机数字表法分为A、B、C三组各46例。A组给予重组人生长激素治疗,B组在A组基础上增加维生素A治疗,C组在B组基础上增加维生素E治疗。比较三组疗效、治疗前后胰岛素样生长因子(IGFs)、胰岛素生长因子结合蛋白-3(IGFBP-3)、生长发育指标(身高、体质量和骨龄)水平,以及不良反应发生率。结果:C组治疗总有效率高于B组和A组,差异均有统计学意义(P<0.05);治疗后,三组IGFs、IGFBP-3水平及身高、体质量和骨龄均高于治疗前,且C组均高于B组和A组,差异有统计学意义(P<0.05);三组患儿不良反应发生率比较,差异无统计学意义(P>0.05)。结论:维生素A、维生素E、重组人生长激素三联治疗矮小症患儿可提高治疗总有效率及IGFs、IGFBP-3和生长发育指标水平,优于单纯重组人生长激素治疗或重组人生长激素联合维生素A治疗效果。
Objective:To observe effects of triple therapy of vitamin A,vitamin E and recombinant human growth hormone on children with short stature.Methods:138 children with short stature were selected as the research objects and were divided into groups A,B and C according to the random number table method,46 cases in each group.Group A received recombinant human growth hormone therapy,Group B received vitamin A therapy on the basis of that of Group A,and Group C received vitamin E therapy on the basis of that of Group B.The clinical effects Before and after treatment,the insulin-like growth factor(IGFs)level,the insulin growth factor-binding protein-3(IGFBP-3)level,the growth and development indicator levels(height,body mass and bone age),and the incidence of adverse reactions were compared among the three groups.Results:The total effective rate of Group C was higher than that of Group B and Group A,and the differences were statistically significant(P<0.05).After the treatment,the levels of IGFs,IGFBP-3,height,body mass and bone age in the three groups were higher than those before the treatment;those of Group C was higher than those of Group B and Group A;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions among the three groups(P>0.05).Conclusions:The triple therapy of vitamin A,vitamin E and recombinant human growth hormone in the children with short stature can improve the total effective rate of treatment,the IGFs,IGFBP-3 and growth and development index levels.Moreover,it is superior to single recombinant human growth hormone therapy or recombinant human growth hormone combined with vitamin A therapy.
作者
李慧
LI Hui(Women&Infants Hospital of Zhengzhou,Zhengzhou 450000 Henan,China)
出处
《中国民康医学》
2022年第7期68-70,共3页
Medical Journal of Chinese People’s Health
